Key Information
Sickle cell anemia is a challenging disease that causes significant morbidity and mortality across the lifespan. But new and emerging therapies, including two new gene therapy treatments available at Penn Medicine, offer hope to patients with this painful condition.
To discuss the current treatment landscape, sickle cell experts Nadia Dawn Ali, MDexternal link, opens in a new tab, and Scott Alan Peslak, MD, PhDexternal link, opens in a new tab, recently joined the Penn Medicine Physician Interviews podcastexternal link, opens in a new tab. Dr. Ali is an Associate Professor of Medicine and Director of the Comprehensive Sickle Cell Programexternal link, opens in a new tab at Penn Medicine. Dr. Peslak is an Assistant Professor of Medicine and Gene Therapy Lead for the Comprehensive Sickle Cell Program and Comprehensive Adult Thalassemia Programexternal link, opens in a new tab.